New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 15, 2013
06:03 EDTGENEGenetic Technologies provides U.S. patent re-examination update
Genetic Technologies announced that the USPTO has now issued an action reaffirming the validity of certain claims contained in the Company's U.S. Patent No. 5,612,179 directed to non-coding DNA. As announced by the Company on July 9, 2012, Genetic Technologies had received formal notification from the USPTO that it had received and granted a request for ex parte re-examination of claims 1-18 and 26-32 of the '179 patent based upon a submission by Merial of Duluth, Georgia. Merial is currently a defendant in an action originally brought by the company in Colorado, USA for infringement of the '179 patent. That action currently is pending in Delaware Federal District Court.
News For GENE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
05:39 EDTGENEGenetic Technologies launches BREVAGenplus in U.S.
Genetic Technologies announce the U.S. launch of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company's first generation product, BREVAGen. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman's five-year and lifetime risk of developing the disease. It is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. The test is directed towards Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ or ductal carcinoma in situ, and have one or more risk factors for developing breast cancer.
September 22, 2014
05:32 EDTGENEGenetic Technologies divests heritage Australian Genetics business for $2M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use